SOM 230 and Gemcitabine in Advanced Pancreatic Cancer

NCT01385956 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: SOM 230 LAR
DRUG: Gemcitabine

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]